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ABSTRACT
The structure-specific ERCC1-XPF endonuclease
plays a key role in DNA damage excision by
nucleotide excision repair (NER) and interstrand
crosslink repair. Mutations in this complex can ei-
ther cause xeroderma pigmentosum (XP) or XP com-
bined with Cockayne syndrome (XPCS-complex) or
Fanconi anemia. However, most patients carry com-
pound heterozygous mutations, which confounds
the dissection of the phenotypic consequences for
each of the identified XPF alleles. Here, we analyzed
the functional impact of individual pathogenic XPF
alleles on NER. We show that XP-causing mutations
diminish XPF recruitment to DNA damage and only
mildly affect global genome NER. In contrast, an
XPCS-complex-specific mutation causes persistent
recruitment of XPF and the upstream core NER ma-
chinery to DNA damage and severely impairs both
global genome and transcription-coupled NER. Re-
markably, persistence of NER factors at DNA damage
appears to be a common feature of XPCS-complex
cells, suggesting that this could be a determining
factor contributing to the development of additional
developmental and/or neurodegenerative features in
XP patients.
INTRODUCTION
Xeroderma pigmentosum (XP) and Cockayne syndrome
(CS) are rare autosomal recessive photosensitive disorders
caused by mutations in genes that encode factors involved
in nucleotide excision repair (NER). XP patients display
pigmentation abnormalities, a >2000-fold increased risk
of skin cancer and over 20% of the patients develop pro-
gressive neurodegeneration (1). CS patients display severe
growth failure, progressive neurodegeneration and segmen-
tal progeria but do not develop cancer (2). XP patients are
classified in complementation groups XP-A to XP-G and
the variant XP-V, according to the mutated gene, while
CS is caused by mutations in the CSA and CSB genes.
Intriguingly, some patients from complementation groups
XP-B, XP-D, XP-G andXP-F combine dermatological fea-
tures of XP with developmental and progressive neurode-
generative features of CS, representing the rare Xeroderma
pigmentosum-Cockayne syndrome (XPCS) complex (3,4).
Also, patients from complementation group XP-A can ex-
hibit XP combined with severe growth failure and progres-
sive neurodegeneration, which is often referred to as De
Sanctis Cacchione (DSC) syndrome (5). The type of disease
and severity of symptoms are thought to depend on which
gene is mutated and to which extent NER is affected, but it
is not properly understood howmutations in the same genes
can cause different diseases.
NER is a major DNA repair pathway responsible for re-
moving UV light induced cyclobutane-pyrimidine dimers
(CPDs) and 6-4 pyrimidine-pyrimidone photoproducts (6-
4PPs) and other bulky lesions such as intrastrand crosslinks
and ROS-induced cyclopurines (6,7). DNA damage is de-
tected by two sub-pathways: global genome-NER (GG-
NER), which detects damage located anywhere in the
genome by the concerted action of the UV-DDB/XPE
and XPC-RAD23B-CETN2 complex, and transcription
coupled-NER (TC-NER), which detects damage in the
template strand of transcribed genes through stalling of
RNApolymerase II and subsequent recruitment of theCSA
(ERCC8), CSB (ERCC6) and UVSSA proteins. Damage
detection by either sub-pathway leads to recruitment of the
basal transcription factor complex IIH (TFIIH). TFIIH
opens the DNA helix and verifies the presence of DNA le-
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sions using its XPB (ERCC3) ATPase and the 5′–3′ helicase
activity of its XPD (ERCC2) subunit, which is stimulated by
the single strand DNA damage binding protein XPA. XPA
binds damaged DNA and interacts with multiple NER fac-
tors and is therefore considered a central NER organizer.
Together with RPA, XPA facilitates the recruitment and
correct positioning of the two structure-specific endonu-
cleases, ERCC1-XPF (XPF is also known as ERCC4) and
XPG (ERCC5), that incise the damaged strand respectively
5′ and 3′ to the lesion. The resulting 22–30 nt gap is then
repaired by DNA synthesis and sealed by ligation.
ERCC1-XPF is an obligate dimer that binds to XPA via
its ERCC1 subunit and incises double stranded DNA 5′ to
a stretch of single stranded DNA using the catalytic activ-
ity of the highly conserved nuclease domain in XPF (8–
11). Besides NER, ERCC1-XPF nuclease activity is also
implicated in removing 3′ overhangs during some forms of
double strand break repair and is critical in unhooking in-
terstrand crosslinks (ICLs) as part of the Fanconi anemia
(FA) repair pathway (12,13). Defects in this latter repair
pathway lead to the rare disease FA, which is character-
ized by congenital growth abnormalities, bone marrow fail-
ure and increased susceptibility to cancer (14). Mutations
in ERCC1-XPF have been found in patients exhibiting a
range of phenotypically pleiotropic diseases including XP,
CS, XPCS and FA, but also the more severe cerebro-oculo-
facio-skeletal syndrome and XPF–ERCC1 progeroid syn-
drome (11,15–18).
The difference in severity of symptoms associated with
ERCC1-XPF defects have been attributed to differences
in mislocalization of the complex to the cytoplasm, which
is observed in many XP-F group patient fibroblasts (19).
There exists wide consensus that XP symptoms are specifi-
cally caused by defects in GG-NER (1) and FA symptoms
by defects in ICL repair (ICLR) (14,20). Thus, mutations
that impair the activity of ERCC1-XPF in either GG-NER
or ICLR will give rise to XP or FA, respectively. The ex-
act etiology of CS is, however, debated and opinions vary
as to whether CS symptoms are primarily caused by defects
in TC-NER or whether defects in other DNA repair path-
ways, transcription, stress responses and/or mitochondria
may play a role as well (6,21–23). It is therefore not under-
stood why certain mutations in ERCC1-XPF only give rise
to XP or FA whereas others in addition cause CS features.
Moreover, in most patients, mutations are present as com-
pound heterozygous and different mutation combinations
are associated with different diseases (Table 1), convoluting
a clear understanding of the contribution of each mutation
to the disease phenotype.
To clarify the molecular mechanism that gives rise to
XPCS, we investigated how specific XPF mutations found
in patients affectedwithXP,XPCSor FA impair the activity
of the ERCC1-XPF complex in response to DNA damage
induction byUV irradiation.We show that XPFwith anXP
mutation is inefficiently recruited into the NER machinery
but retains repair activity. Conversely, XPCS mutant XPF
persists at sites of DNA damage and hardly displays repair
activity, leading to continuous recruitment of the core NER
machinery.
MATERIALS AND METHODS
Cell culture, generation of cell lines and cloning of XPF-GFP
constructs
U2OS cell lines were cultured in a 1:1 mixture of DMEM
and F10 supplemented with 10% fetal calf serum (FCS)
and 1% penicillin-streptomycin (PS) at 37◦C and 5% CO2.
Wild type hTERT immortalized C5RO and patient fibrob-
lasts XPCS1CD, CS1USAU (15), hTERT immortalized
XP42RO (24), XP32BR (19), XP6BE (25), hTERT im-
mortalized XPCS1RO (26), XPCS2 (27), XPCS1BA (28)
and XP25RO (29) were cultured in F10 supplemented
with 15% FCS and 1% PS at 37◦C and 5% CO2. To
generate U2OS XPF KO cells, U2OS cells were simul-
taneously transfected with pLentiCRISPR-V2 plasmids
(30) containing an sgRNA targeting exon 1 (TGGAACT
GCTCGACACTGAC) and an sgRNA targeting exon 2
(CGCTATGAAGTTTACACACA) of XPF. Following se-
lection with puromycin, single XPF KO clones were an-
alyzed by immunoblot and sequencing. Tracking Indels
by Decomposition analysis was performed as described
in Brinkman et al. (31). To generate GFP-tagged wild
type XPF (XPF-wt), full length XPF cDNA, kindly pro-
vided by Orlando D. Scha¨rer, was fused to GFP at its C-
terminus and cloned into pLenti-CMV-Blast-DEST (32).
GFP-tagged XPF mutants were generated by site directed
mutagenesis using primers listed in Supplementary Table S1
and cloned into pLenti-CMV-Blast-DEST or pLenti-CMV-
Puro-DEST. GFP-tagged wild type and mutant XPF were
introduced in U2OS XPF KO cells by lentiviral transduc-
tion and cells were selected using blasticidin or puromycin.
Cloning details are available upon request.
Clonogenic survival assays
To determine UV and mitomycin C (MMC) sensitivity, 500
cells were seeded in triplicate in six-well plates. 24 h after
seeding, cells were irradiated with UV (0, 0.5, 1, 2, 4 J/m2;
254 nm UV-C lamp, Philips) or treated with MMC (0, 0.3,
0.6, 0.9, 1.2, 1.5 g/ml; Sigma). After 5–7 days, cells were
fixed and stained with 50% methanol, 7% acetic acid, 0.1%
Brilliant Blue R (Sigma) and counted using the integrated
colony counter GelCount (Oxford Optronix). The number
of colonies after treatment was normalized to the number in
non-treated conditions and plotted as average survival per-
centage of three independent experiments. Statistical differ-
ence was calculated using a paired two-tailed Student’s t-
test.
Live cell imaging and fluorescence recovery after photo-
bleaching (FRAP)
For live cell imaging, cells were seeded on coverslips and
imaged with a Leica TCS SP5 confocal microscope using a
63x/1.4 NA HCX PL APO CS oil immersion lens (Leica
Microsystems) at 37◦C and 5% CO2. FRAP was performed
as previously described (33). Briefly, fluorescence was im-
aged within a strip of 512 × 16 pixels stretched over the
width of the nucleus (zoom 9×) at 1400 Hz every 22 ms us-
ing 488 nm laser at low power until steady-state levels were
reached. Next, fluorescence signal was bleached using high
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Table 1. Features of studied XPF mutations
Amino
acid
change
Nucleotide
change
Compound
heterozy-
gous
with Cell line Diseasea
UV
sensitivityb
MMC
sensitivityb UDSc RRSc Reference
C236R 706T > C R589W XPCS1CD XPCS +
FA features
+ + 8% 24% (15)
Y577* CS1USAU XPCS + - 10% 16% (15)
P379S 1135C > T R589W XP32BR mild XP + ND 10–16% ND (19,39)
XP72BR mild XP ND 36% ND (39)
silent allele XP7NE mild XP + ND 30% ND (19)
R589W 1765C > T P379S XP32BR mild XP + ND 10–16% ND (15,39)
R799W XP24BR severe XP,
neurode-
generation
+ ND 4–5% ND (15,19,39)
del exon 3 AS871 severe XP,
neurode-
generation
+ ND 15% ND (15,19)
C236R XPCS1CD XPCS +
FA features
+ + 8% 24% (15)
R689S 2065C > A T495Nfs*6 FA104 FA - + ND ND (16)
D715A 2144A > C ND ND ND ND (8)
S786F 2357C > T - + ND ND (40)
aXP: xeroderma pigmentosum; CS: Cockayne syndrome; XPCS: xeroderma pigmentosum-Cockayne syndrome; FA: Fanconi anemia.
b+ hypersensitive to either UV or MMC; - not hypersensitive; ND, not determined.
cRRS and UDS levels in XPCS1CD and CS1USAU were estimated based on graphs in Figure 1C and D of (15).
laser power (100%) and recovery of the signal wasmeasured
at low laser power every 22 ms until steady-state levels were
reached. To perform FRAP on local UV damaged areas
(Figure 3D), the entire nucleus of each cell was imaged at
400 Hz every 648 ms using low laser power. Fluorescence
signal within a small region (1.5 m × 1.5 m) stretched
over the local damage area was bleached with high laser
power and recovery of the fluorescence in time was mea-
sured at low laser power every 648 ms. Fluorescence signals
were normalized to the average fluorescence intensity before
bleaching and bleach depth. The immobile fraction (Fimm)
(Figure 3C) was determined using the fluorescence inten-
sity measured immediately after bleaching (I0), and the av-
erage steady-state fluorescence level once recovery was com-
plete, from untreated cells (Ifinal, unt) and UV- treated cells
(Ifinal, UV) and applying the formula: Fimm = 1 – (Ifinal,UV −
I0,UV)/(Ifinal,unt − I0,uv) (34). Statistical difference was calcu-
lated using an unpaired two-tailed Student’s t-test. LASAF
software (Leica) was used for imaging and quantification.
Immunofluorescence
To perform immunofluorescence experiments, cells were
seeded on coverslips and, when indicated, irradiated with
60 J/m2 (254 nm UVC lamp, Philips) through an 8 m mi-
croporous filter (Millipore) to inflict local DNAdamage. To
determine CPD removal, cells were globally irradiated with
10 J/m2. Cells were fixed at the indicated time points with
2% paraformaldehyde and 0.1%Triton X-100 and perme-
abilized for 20 min using 0.1% Triton X-100 in PBS. To vi-
sualize CPDs, cells were incubated with 0.07 M NaOH in
PBS for 5 min to denature DNA. Cells were then washed
with PBS containing 0.15% glycine and 0.5% BSA and in-
cubated with primary antibodies for 2 h. After thorough
washing with PBS containing 0.1% Triton X-100, cells were
incubated with Alexa Fluor conjugated secondary antibod-
ies (488, 555 and 633; Invitrogen) for 1 h. Coverslips were
mounted using DAPI Vectashield (Vector Laboratories)
and imaged using an LSM700 microscope equipped with
a 40x Plan-apochromat 1.3 NA oil immersion lens (Carl
Zeiss). Quantification of repair protein recruitment or CPD
signal was performed using FIJI image analysis software.
Statistical difference was calculated using an unpaired two-
tailed Student’s t-test. Primary antibodies used were against
XPF (sc-136153, Santa Cruz Biotechnology), XPC (home-
made fraction 5 or A301-121A, Bethyl), ERCC1 (ab129267,
Abcam), GFP (ab290, Abcam), CPD (TDM-2; Cosmobio),
XPB (sc-293, Santa Cruz), XPD (ab54676, Abcam), XPG
(A301-484A, Bethyl) andXPA (sc-853, Santa Cruz Biotech-
nology).
Cell fractionation
For cell fractionation, cells were irradiated with 5 J/m2
UVC (254 nm lamp, Philips) or left untreated. Cells
were collected by trypsinization, washed and incubated in
HEPES Buffer (30 mM HEPES pH 7.5, 130 mM NaCl,
1mM MgCl2, 0.5% triton X-100 and protease inhibitors)
on ice for 30 min. Samples were centrifuged at 15 000g for
20 min and separated into supernatant (soluble fraction)
and pellet (chromatin fraction), which was solubilized by
treatment with 250Uof benzonase (MerckMillipore). Both
fractions were analyzed by immunoblot. Statistical differ-
ence was calculated using a paired two-tailed Student’s t-
test.
Immunoblot
For immunoblot analysis, cells or samples were collected in
2× sample buffer (125 mM Tris–HCl pH 6.8, 20% glycerol,
10% 2--mercaptoethanol, 4% SDS, 0.01% Bromophenol
Blue) and boiled at 98◦C for 5 min. Protein lysate was sepa-
rated by SDS-PAGE and transferred to a PVDFmembrane
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(0.45 m, Merck Millipore). Membranes were blocked in
2% BSA and incubated with primary and secondary anti-
bodies for 2 h or overnight. Antibodies used were against
XPF (sc-136153, Santa Cruz), ERCC1 (sc-17809, Santa
Cruz), CSB (sc-10459, Santa Cruz), H2B (sc-8650, Santa
Cruz) and Ku-70 (sc-17789, Santa Cruz Biotechnology).
Secondary antibodies were conjugated with CF IRDye 680
or 770 (Sigma) and visualized using the Odyssey CLx In-
frared Imaging System (LI-COR Biosciences).
Recovery of RNA synthesis
RRS was performed as described (35). Briefly, cells were
mock treated or irradiated with 6 J/m2 UVC (254 nm lamp,
Philips) and RNA was labeled 24 h later by incubation
with EU for 1 h. Cells were fixed in 4% paraformaldehyde
and permeabilized with 0.1% Triton X-100 in PBS. To vi-
sualize EU incorporation, cells were incubated in Click-it
buffer containing Atto 594 Azide (60 M, Atto Tec.), Tris-
HCl (50 mM, pH 7.6), CuSO4.5H2O (4 mM, Sigma) and
ascorbic acid (10 mM, Sigma) for 1 h and then washed
with PBS containing 0.1%TritonX-100. DAPI (Sigma) was
used to stain DNA and slides were mounted using Aqua-
Poly/Mount (Polysciences, Inc.). Images were acquired us-
ing an LSM700 confocal microscope equipped with a 40×
Plan-apochromat 1.3NAoil immersion lens (Carl ZeissMi-
cro Imaging Inc.). RRS levels were quantified by averaging
the total nuclear fluorescence intensities of at least 100 cells
per experiment with FIJI image analysis software and nor-
malization to fluorescence levels in control conditions.
Unscheduled DNA synthesis
UDS was measured in local UV damaged areas within
cells after irradiation with 60 J/m2 (254 nm UVC lamp,
Philips) through an 8 m microporous filter (Millipore).
Cells were incubated with EdU for 30 min or 1 h, pre-
extracted with PBS containing 0.1% Triton X-100 and fixed
with 2% paraformaldehyde in PBS. Next, cells were perme-
abilized using PBS containing 0.1%TritonX-100 for 10min
and blocked in PBS containing 1.5% BSA for 10 min. To
visualize CPDs, DNA was denatured with 0.07 M NaOH
for 5 min. To visualize EdU incorporation, cells were in-
cubated in Click-it buffer containing Atto 594 Azide (60
M, Atto Tec.), Tris–HCl (50 mM, pH 7.6), CuSO4*5H2O
(4 mM, Sigma) and ascorbic acid (10 mM, Sigma) for 1 h
and then washed with PBS containing 0.1% Triton X-100.
Subsequently, cells were washedwith PBS containing 0.15%
glycine and 0.5%BSA and incubated withGFP (ab290, Ab-
cam) and CPD (TDM-2; Cosmobio) antibodies for 2 h. Af-
ter washing with PBS containing 0.1% Triton X-100 and
PBS, cells were incubated with Alexa Fluor conjugated sec-
ondary antibodies (488 and 633; Invitrogen) for 1 h. Cover-
slips were mounted using DAPI Vectashield (Vector Labo-
ratories) and imaged using anLSM700microscope and 40×
Plan-apochromat 1.3 NA oil immersion lens (Carl Zeiss).
The fluorescent EdU signal at local sites of damage from at
least 60 cells per condition was quantified using FIJI image
analysis and averaged. Statistical difference was calculated
using an unpaired two-tailed Student’s t-test.
RESULTS
Generation of XPF knockout and XPF-GFP expressing cells
To study how XPF deficiency can lead to different diseases,
we determined how XPF mutations found in XP, XPCS
and FA patients affect the spatio-temporal response of the
ERCC1-XPF complex toDNAdamage. To this end, we first
generated an XPF knockout (KO) cell line, to be able to
compare different mutant XPF proteins, which in patients
most often occur as compound heterozygous, in the same
genetic background. Following transfection of U2OS cells
with plasmids expressing Cas9 and sgRNAs targeting exon
1 and exon 2 of XPF, we selected an XPF KO clone carry-
ing multiple indel mutations in both exons predicted to lead
to early truncation of the protein, as revealed by sequencing
and tracking indels by decomposition analysis (31) (Supple-
mentary Figure S1). In this clone, XPF was not detectable
by immunoblot nor by immunofluorescence (Figure 1A-B).
To functionally confirm the absence of XPF, we determined
protein levels of ERCC1, whose stability depends on the
presence of XPF (36,37), and found these to be strongly
reduced in the XPF KO cells (Figure 1A). Moreover, ex-
treme hypersensitivity to UV (Figure 1C), which generates
lesions that are substrates for NER, and to Mitomycin C
(MMC; Figure 1D), which in addition induces ICLs, con-
firmed that these KO cells lack XPF activity and are there-
fore completely NER- and ICLR-deficient. Next, we stably
expressedGFP-tagged wild type XPF (XPF-wt) in the XPF
KO cells, which rescuedUV andMMChypersensitivity and
stabilized protein levels of ERCC1 (Figure 1A, C and D).
To further validate the functionality of XPF-wt, we applied
UVC irradiation through a microporous filter to inflict lo-
cal DNA damage within the nuclei of the cells (38). XPF-
wt clearly accumulated at sites of local UV damage (LUD)
marked by XPC, in cells fixed 30 min after irradiation, simi-
larly to endogenous XPF in control U2OS cells (Figure 1B).
Together, these data indicate that repair deficient XPF KO
cells can be fully complemented by GFP-tagged wild type
XPF.
XP, XPCS and FA mutations differently affect UV and
MMC sensitivity
Next, we stably expressed GFP-tagged XPF mutants mim-
icking alleles previously reported in patients affected with
XP, XPCS and FA in the XPF KO cells (Table 1 and Fig-
ure 2A). We introduced two amino acid substitutions in the
helicase-like domain of XPF: P379S (XPF-P379S), found
in patients affected with mild XP (39) and C236R (XPF-
C236R), found in XPCS patients (15). We also introduced
the R589W substitution (XPF-R589W), found as com-
pound heterozygous together with P379S in mild XP but
together with C236R in XPCS with FA features (15,19,39).
Furthermore, we generated nuclease domain substitution
mutants R689S (XPF-R689S), found in an XPF FA patient
(16) and S786F (XPF-S786F), which was reported to dis-
rupt ICLR but not NER (40). As control, we generated a
nuclease-dead mutant unable to cleave DNA, by introduc-
ing the D715A substitution (XPF-D715A) (8).
Live cell imaging and immunofluorescence showed that
all XPF mutants, except XPF-R589W, localized exclusively
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Figure 1. Generation of XPF knockout and XPF-GFP expressing cells. (A) Immunoblot showing XPF and ERCC1 expression in U2OS, XPF knockout
(KO) and XPF-GFP (XPF-wt) expressing XPFKO cells. Ku70 staining is shown as loading control. (B) Immunofluorescence pictures showing localization
of endogenous XPF in U2OS (top panel) and XPF-wt in XPF KO cells (bottom panel) to LUD induced by 60 J/m2 UVC irradiation through an 8 m
microporous filter. Cells were fixed 30 minutes after UV and stained against XPF and XPC, to mark sites of local damage. Scale bar: 5 m. (C) Clonogenic
UV survival assays of U2OS, XPF KO and XPF-wt expressing XPF KO cells. (D) Clonogenic MMC survival assays of U2OS, XPF KO and XPF-wt
expressing XPF KO cells. Survival assays are plotted as average of three independent experiments, each performed in triplicate. Error bars represent the
SEM. Statistical significant difference (P < 0.05) compared to U2OS for each dose is indicated by *.
in the nucleus (Figure 2B-C). ERCC1 is stabilized by its in-
teraction with XPF and translocates to the nucleus only
when in complex with nuclear XPF (19,36,37,41). Notice-
ably, in all cell lines expressing XPF mutants, except in the
cell line expressing the R589Wmutant, ERCC1 protein lev-
els were increased (Supplementary Figure S1B; compare
with XPF KO in Figure 1A) and ERCC1 was clearly lo-
calized in the nucleus compared to XPF KO (Figure 2C).
These results indicate that these XPF mutants interact nor-
mally with ERCC1, which was previously also shown for
C236R, R689S and D715A XPF mutants (8,15,16). The
only exception was XPF-R589W, which showed predom-
inant or exclusive localization in the cytoplasm in ∼54%
of cells and equal localization in cytoplasm and nucleus in
∼44% of cells (Figure 2B). Although this mutant appeared
to stabilize ERCC1 levels on immunoblot (Supplementary
Figure S1B), in immunofluorescence no clearly increased
ERCC1 levels were observed, not even when XPF was also
partially localized in the nucleus (Figure 2C). To determine
the impact of each separate mutation on the different func-
tions of XPF in NER and ICLR, we measured sensitivity
of each cell line to UV irradiation and MMC. This showed
that cells expressing the C236R, R589W and D715A XPF
mutants were strongly hypersensitive to UV (Figure 2D),
but cells expressing the P379S, R689S and S786F XPF mu-
tants only showed mild to hardly any UV sensitivity. Cells
expressing the C236R, R589W and D715A XPF mutants
were also strongly hypersensitive to MMC, while cells ex-
pressing XPF-P379S were not sensitive to MMC (Figure
2E). However, contrarily to their mild UV survival, cells ex-
pressing XPF-R689S and XPF-S786F were hypersensitive
to MMC. These data indicate that XPF mutations found
in mild XP and FA patients, i.e. P379S and R689S, and the
ICLR-defective S786F mutation, do not fully compromise
the ability of XPF to function in NER. R689S and S786F
nonetheless do impair XPF function in ICLR. The C236R
mutation found in XPCS patients, of which one has features
of FA, impedes XPF function in NER and possibly also in
ICLR, but this latter is difficult to judge becausemildMMC
sensitivity can also be caused by a NER defect (17,42).
Strikingly, XPF-R589W was unable to complement both
NER and ICLR, similar as nuclease-dead XPF-D715A.We
therefore conclude that R589W, which causes XPF to local-
ize in the cytoplasm and is only found in compound het-
erozygous combinations in patients (Table 1) (15,19,39), is
a functional null mutation.
Impaired recruitment of XPF-P379S contrasts persistent re-
cruitment of XPF-C236R
To better understand the activity of each XPF mutant in
NER, we determined LUD recruitment of the mutants at
multiple time points after UV irradiation through a mi-
croporous filter using immunofluorescence. LUD was vi-
sualized using CPD staining, which is commonly used as
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Figure 2. Expression of XPFmutants and sensitivity to UV andMMC. (A) Schematic representation of the XPF protein and annotation of the amino acid
substitutions studied in this paper. (B) Live cell images showing the subcellular distribution of GFP-tagged XPF-wt and XPF mutants stably expressed in
U2OS XPF KO cells. Scale bar: 20 m. (C) Immunofluorescence images showing the subcellular distribution of GFP-tagged XPF-wt and XPF mutants
stably expressed in XPF KO cells, together with ERCC1 expression visualized by staining with an antibody against ERCC1. Scale bar: 10 m. (D,E)
Clonogenic survival assays showing the sensitivity to UV (D) andMMC (E) treatment of XPFKO cells expressing XPFmutants compared to U2OS, XPF
KO only and XPF-wt expressing cells. Results are plotted as average of three (UV) or two (MMC) independent experiments, each performed in triplicate.
Error bars represent the SEM. Statistical significant difference (P < 0.05) compared to U2OS or XPF-wt for each dose is indicated by *.
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Figure 3. XPF-P379S shows diminished and XPF-C236R persistent DNA damage recruitment. (A) Representative immunofluorescence pictures of LUD
recruitment of XPF-wt and XPF mutants 1 h and 24 h after local UV irradiation (60 J/m2) through an 8 m microporous filter. Cells were stained
with antibodies against GFP and CPD, as damage marker. Cells showing clear and comparable local CPD staining are depicted. Scale bar: 5 m. (B)
Quantification of LUD recruitment of XPF-wt and XPF mutants, at 1, 2, 4, 8 and 24 h after UV irradiation (60 J/m2) through a microporous filter,
determined by immunofluorescence as shown in (A) and in Supplementary Figure S2A. The fold accumulation was calculated by normalizing fluorescence
intensity at sites of local damage to the nuclear background and plotted as average of at least 60 cells per condition from two independent experiments.
Statistical significant difference (P < 0.05) compared to wt for each time point is indicated by *. (C) Percentage immobile fraction of XPF-wt and XPF
mutants following UV irradiation (5 J/m2), as determined by FRAP analysis, shown in Supplementary Figure S2B, of at least 20 cells per condition from
at least two independent experiments. Statistical significant difference (P < 0.05) compared to wt is indicated by *. In (B) and (C), error bars represent the
SEM. (D) FRAP analysis of XPF-wt, XPF-P379S (1 h after UV) and XPF-C236R (1 and 6 h after UV) accumulated at LUD, inflicted by 60 J/m2 UVC
through an 8 m microporous filter. Each curve represents the average of 30 cells per condition from at least three different experiments. RFI indicates
relative fluorescence intensity.
a marker for sites of UV damage because CPDs are only
very slowly repaired in human cells (43) and still visible up
to 24 h after DNA damage induction. XPF-wt clearly ac-
cumulated at 1 h and 2 h after UV and showed gradual
diminished recruitment at later time points (Figure 3A-B
and Supplementary Figure S2A). XPF-R689S and XPF-
S786F showed similar recruitment kinetics, albeit XPF-
R689S showed slightly delayed release from sites of damage.
In contrast, XPF-P379S was inefficiently recruited to LUD
at early time points whereas its recruitment also gradually
diminished at later time points. Strikingly, XPF-C236R, as
well as the nuclease dead XPF-D715A, were strongly re-
cruited at all time points and, remarkably, still persisted at
LUD at 24 h. XPF-R589W did not accumulate at all to
LUD, even in cells that showed some nuclear localization
of the mutant protein, confirming that this is a null muta-
tion.
To further study the dynamic interaction of each of
the XPF mutants with UV-irradiated, damaged chromatin,
we performed fluorescence recovery after photobleaching
(FRAP) in untreated and UV treated cells immediately af-
ter irradiation. In untreated cells, all tested XPF mutants
showed comparable mobility to XPF-wt, indicating that the
mutations do not interfere with XPF’s ability to freely move
through the nucleus (Supplementary Figure S2B). XPF-
R589W could not be tested because its nuclear expression
was too low to perform FRAP. Upon UV treatment, in-
complete fluorescence recovery of XPF-wt was observed
due to XPF immobilization onUV-damaged chromatin, re-
flecting active participation in NER (33). The fraction of
immobilized wild type XPF after 5 J/m2 UVC was calcu-
lated to be around 12% (Figure 3C). Similar UV-induced
immobilization was observed for XPF-S786F while XPF-
R689S showed increased immobilization compared to wild
type, in accord with its slightly delayed release from LUD
observed with immunofluorescence (Figure 3C and Supple-
mentary Figure S2B). Also in line with the immunofluores-
cence, we observed diminished UV-induced immobilization
for XPF-P379S, suggesting that this XP mutant is not effi-
ciently recruited or less stably bound toUVdamage. In con-
trast, XPF-C236R andXPF-D715A showedmuch stronger
UV-induced immobilization than XPF-wt. These data, to-
gether with the prolonged LUD accumulation observed in
immunofluorescence, indicate that although both mutants
are efficiently recruited by the NERmachinery, their release
from UV damage sites is impaired. This prolonged reten-
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tion at UV damage sites is likely because both mutants can-
not efficiently incise damaged DNA during NER, as it was
found that the C236R and D715A mutations respectively
reduce (15) and disrupt (8) XPF endonuclease activity in
vitro.
Because of the strong and prolonged accumulation of
XPF-C236Rat LUDsites, we investigated if in time thismu-
tant becomes permanently bound to sites of damage or if it
is still dynamically binding and dissociating. To this aim, we
performed FRAP on LUD inflicted through a microporous
filter to measure the mobility (association/dissociation) of
XPF-C236R at sites of DNA damage 1 and 6 h after irra-
diation. As comparison, we measured the mobility of XPF-
wt and XPF-P379S on LUD 1 h after UV. Although mu-
tant XPF-P379S was capable of accumulating at LUD (in
reduced amounts), its faster recovery of fluorescence after
bleaching as compared toXPF-wt (Figure 3D) suggests that
this mutant is swiftly exchanged with non-bound XPF. Re-
cruitment and binding of ERCC1-XPF to damaged DNA
is thought to be mediated by an interaction of ERCC1 with
XPA (9,10,44,45), while XPF activity may be stimulated by
an interaction with RPA (46). Thus, it may be that a mu-
tated ERCC1-XPF-P379S complex has reduced affinity for
one of these proteins or is less well able to bind to DNA.
Interestingly, XPF-C236R at both the 1 and 6 h time points
after UV showed increased initial immobilization but its
fluorescence slowly recovered in time (the ascending slope
of the FRAP curve in Figure 3D), reflecting delayed but
still continuous dissociation. These data confirm that XPF-
P379S is inefficiently incorporated into the NER incision
complex. Conversely, XPF-C236R is not released as effi-
ciently as XPF-wt, i.e. as when damage is excised, but it
likely associates and dissociates continuously to deal with
persistent NER substrates.
The NER machinery is continuously recruited to DNA dam-
age in the absence of XPF incision
Next, we investigated how the different recruitment be-
havior of XPF-P379S and XPF-C236R affects the DNA
damage recruitment of upstream NER factors, using im-
munofluorescence. In cells expressing XPF-wt and XPF-
P379S, XPC, XPB, XPG and XPA (Figure 4) clearly accu-
mulated at sites of local damage, marked by CPD staining,
1 h after UV and had disappeared after 8 h. In contrast, in
XPF KO cells and cells expressing XPF-C236R, as well as
in cells expressing catalytically inactive XPF-D715A, accu-
mulation of theseNER factors was still clearly visible 8 h af-
ter UV. Moreover, also in cells expressing the XPF-R589W
null mutant in the nucleus, XPB localization at LUD per-
sisted up to 8 h after UV (Figure 4C). As LUD recruit-
ment of TC-NER factors, such as CSB, is difficult to vi-
sualize using immunofluorescence, we measured chromatin
binding of CSB after UV using cellular fractionation. CSB
was strongly enriched in chromatin of all cells 1 h after
irradiation but showed delayed release from chromatin in
XPF-P379S and XPF-C236R expressing cells, which was
strongest for XPF-C236R (Figure 5). Taken together, these
data indicate that in the absence of XPF-mediated incision,
also upstream NER factors XPC, TFIIH, XPA, XPG and
CSB are continuously recruited to sites of damage and/or
less efficiently dissociated, likely in a vain attempt to repair
persisting lesions.
XPF-P379S still allows slow repair while XPF-C236R blocks
repair
To explore how NER activity itself is affected by XPF-
P379S and XPF-C236R, we determined TC- andGG-NER
capacity by measuring respectively recovery of RNA syn-
thesis (RRS) after UV-induced transcription inhibition and
unscheduled DNA synthesis (UDS) after UV in XPF KO
cells expressing both mutant proteins. RRS, quantified by
measuring 5-ethynyluridine (EU) incorporation into RNA
24 h after UV, showed that TC-NER was severely affected
inXPFKOandXPF-C236R cells but not in cells expressing
XPF-wt or XPF-P379S (Figure 6A). UDS was determined
by quantifying incorporation of 5-ethynyl-2-deoxiuridine
(EdU) for 30 and 60 min. We measured EdU levels at LUD
sites, to be sure that UDS measurements were not obscured
by EdU incorporated during replication in the rapidly pro-
liferating U2OS cells. UDS levels in XPF-P379S cells in-
creased from 30 to 60 min but were lower than in XPF-wt
cells, indicating that repair took place but less efficiently.
However, strikingly, XPF-C236R cells only showed base-
lineUDS levels that did not increase in time, suggesting that
these cells are severely deficient inGG-NER (Figure 6B). To
confirm this, we measured clearance of CPD lesions in 24 h
by immunofluorescence after global UV irradiation of cells.
This showed that CPDs are indeed repaired in XPF-P379S
cells, although with slight delay as compared to U2OS and
XPF-wt cells (Figure 6C). Both XPF KO and XPF-C236R
cells did not repair CPDs. These results indicate that the
C236Rmutation leads to a much stronger NER defect than
the P379S mutation, causing impaired transcription after
DNA damage, which may very well explain the more severe
and CS-like features in patients carrying this mutation.
Continuous recruitment of the NER machinery is a common
feature of XPCS cells
To verify that also in XPCS complex patient cells the NER
machinery persistently binds toDNAdamage, we tested the
DNA damage recruitment of XPF and XPB in CS1USAU
and XPCS1CD fibroblasts that carry the C236R mutation
in XPF (Table 1) (15). XPF and XPB clearly co-localized
in nuclear LUD foci in wild type C5RO fibroblasts as well
as in the XPCS fibroblasts 1 h after UV (Figure 7A). No
co-localization was observed 8 h after UV in wild type fi-
broblasts, due to removal of lesions, but intriguingly the co-
localization did not disappear in XPCS cells.
Next, we investigated whether persistent recruitment of
NER proteins is a specific feature also of other XPCS com-
plex patient fibroblasts, which is not observed in cells from
patients affected by XP only, and whether similar persistent
recruitment can be observed in cells from severe DSC syn-
drome. Therefore, we tested the LUD recruitment of XPC,
TFIIH subunits XPB and XPD, XPA, XPG and XPF in
XP patient fibroblasts carrying mutations in XPD or XPF,
in XPCS complex patient fibroblasts carrying mutations in
XPB, XPD, XPG or XPF and in DSC patient fibroblasts
carrying a mutation in XPA. In wild type and XP fibrob-
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Figure 4. The NERmachinery is continuously recruited at sites of DNA damage in XPFKO and XPF-C236R expressing cells. Representative immunoflu-
orescence pictures and quantification of LUD recruitment of XPC (A and B), XPB (C and D), XPG (E and F) and XPA (G and H) 1 h and 8 h after 60
J/m2 UVC irradiation through an 8 m microporous filter in XPF KO cells and cells expressing XPF-wt, XPF-P379S, XPF-C236R, XPF-D715A and
(only in C) XPF-R589W. UV damage was visualized by CPD staining. Scale bar: 5 m. Fold accumulation was calculated by normalizing fluorescence
at sites of local damage to the nuclear background and plotted as average of at least 111 (XPC), 85 (XPB), 137 (XPG) and 105 (XPA) cells per condition
from at least two independent experiments. Statistical significant difference (P < 0.05) compared to wt for each time point is indicated by *.
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Figure 5. Delayed CSB release from chromatin in XPF-P379S and XPF-
C236R cells. Representative cell fractionation of XPF-wt, XPF-P379S and
XPF-C236R cells analyzed by immunoblot against CSB andH2B (as load-
ing control; upper panel). Cells were mock treated (–) or irradiated with 5
J/m2 UVC, lysed after 1 h and 8 h and fractionated into non-chromatin
bound (soluble) and chromatin-bound proteins. Lower panel shows quan-
tified levels of CSB bound to the chromatin relative to H2B averaged from
four independent experiments. Error bars indicate SEM. Statistical signif-
icant difference (P< 0.05) compared to wt for each time point is indicated
by *.
lasts, XPC, XPB, XPD, and XPG localized to sites of dam-
age 1 h afterUVand had (mostly) disappeared at 8 h (Figure
7B and Supplementary Figures S3 and S4; Table 2). Simi-
lar transient recruitment was observed for XPA in wild type
and XPF-deficient XP cells, but XPA recruitment was not
observed in XPD-deficient XP cells (Supplementary Fig-
ure S5), likely because XPA acts downstream of TFIIH.
XPF LUD recruitment was not clearly visible in the XPF-
deficient XP-patient cells XP32BR, expressing R589W and
P379S mutant XPF, and XP42RO, expressing XPF with a
R799W mutation. This result is in line with the diminished
recruitment we had observed for XPF-P379S and may in-
dicate that, similarly, XPF carrying a R799W mutation is
less efficiently recruited. In contrast, in XPCS cells, we ob-
served persistent DNA damage recruitment of XPC, XPB
and XPD at 8 h after UV. Persistent XPA and XPF recruit-
ment was only clearly observed in XPF- and XPG-deficient
XPCS cells, but not in XPB- and XPD-deficient cells. XPG
also persisted at LUD in XPF-deficient XPCS cells but its
recruitment, even at 1 h, could hardly be discerned in XPB-
andXPD-deficient XPCS cells. Intriguingly, DSC patient fi-
broblasts also showed persistent recruitment of XPC, XPB
and XPD. These data indicate that continuous DNA dam-
age recruitment of part of the core NER machinery, i.e.
XPC and TFIIH, is a general feature of cells derived from
XP patients showing additional CS features and/or severe
growth and progressive neurological defects.
DISCUSSION
As most ERCC1-XPF patient mutations manifest as com-
pound heterozygous, obscuring a clear understanding of
their individual pathogenic impact, we individually ex-
pressed XPF mutants in XPF KO cells to study how
each mutation affects ERCC1-XPF activity in NER. XP-
associated P379S mutant XPF, which in patients is found
homozygous or heterozygous with a silent allele or the null
allele R589W (Table 1) (19,39), was inefficiently recruited to
DNA damage. Still, this mutant conserved significant resid-
ual repair capacity, as shown by increasing UDS levels and
repair of CPDs in time. Thus, P379S does not fully abolish
but only slows down NER, explaining the almost complete
transcription recovery after UV and very mild UV sensi-
tivity observed with this mutant. This is in agreement with
significant UDS levels reported for XP72BR, XP7NE and
XP32BR patient fibroblasts carrying this mutation (19,39)
(Table 1). Intriguingly, Fassihi et al. noticed that P379S
occurs with a high allele frequency of 0.3% in the SNP
database which would predict more homozygous P379S in-
dividuals than patients currently diagnosed with XP (39).
Our results, showing that this mutation only mildly impairs
ERCC1-XPF activity in NER, might explain this disparity.
Residual GG-NER activity has also been reported in cells
expressing another XP-associated XPFmutant, i.e. R799W
(16,19,24). In XP42RO fibroblasts expressing this mutant,
we hardly observedDNAdamageXPF recruitment but also
did not notice persistent recruitment of the upstream NER
Table 2. Localization of NER factors to LUD in XP, XPCS and DSC patient fibroblasts.
1 h 8 h 1 h 8 h 1 h 8 h 1 h 8 h 1 h 8 h 1 h 8 h
disease cell line gene affected XPC XPC XPB XPB XPD XPD XPA XPA XPG XPG XPF XPF
C5RO + - + - + - + - +- - + -
XP XP42RO XPF (R799W) + - + - + +- + - + - - -
XP XP32BR XPF (R589W P379S) + - + - + - + - + - - -
XP XP6BE XPD (R683W) + - +- +- + - - - +- +- +- -
XPCS XPCS1CD XPF (C236R R589W) + + + + + + + + + + + +
XPCS XPCS1BA XPB (F99S) + + +- +- + + - - - - +- -
XPCS XPCS2 XPD (G602D) + +- + +- + + + +- +- +- + -
XPCS XPCS1RO XPG (926fs) + + + + + + + + - - + +
DSC XP25RO XPA (R207X) + + + + + + - - + - - -
+(almost) always visible.
+-intermediate visible.
-not or hardly visible.
XP: xeroderma pigmentosum.
XPCS: xeroderma pigmentosum-Cockayne syndrome.
DSC: De Sanctis Cacchione.
D
ow
nloaded from
 https://academ
ic.oup.com
/nar/article-abstract/46/18/9563/5079703 by Erasm
us U
niversity R
otterdam
 user on 23 O
ctober 2018
Nucleic Acids Research, 2018, Vol. 46, No. 18 9573
U2OS XPF KO XPF-wt P379S C236R 
no
 U
V 
24
h 
GFP EdU CPD DAPI 
XP
F-
w
t 
30
 m
in
 
1 
h 
P3
79
S 30
 m
in
 
1 
h 
C
23
6R
 
30
 m
in
 
1 
h 0
10
20
30
40
XPF-wt P379S C236R
Ed
U
 in
co
rp
or
at
io
n 30 min 1 h
A B
0.0
0.2
0.4
0.6
0.8
1.0
1.2
U2OS XPF KO XPF-wt P379S C236R
EU
 in
co
rp
or
at
io
n no UV 24 h
C
0
20
40
60
80
100
120
U2OS XPF KO XPF-wt P379S C236R
%
 C
PD
 le
ve
l 
1 min after UV
24 h after UV*
*
*
*
*
* *
*
Figure 6. NER is delayed by XPF-P379S and strongly inhibited by XPF-C236R. (A) RRS measured by EU incorporation 24 h after mock-treatment (no
UV) or 6 J/m2 UVC in U2OS, XPF KO and XPF-wt, XPF-P379S and XPF-C236R expressing cells. Upper panel shows representative images of red
nuclear EU staining. Lower panel shows quantified EU incorporation levels averaged from at least 100 cells in two independent experiments. Scale bar: 25
m. (B) UDS determined by measuring EdU incorporation at LUD sites for 30 min and for 1 h after UV irradiation (60 J/m2) inflicted through an 8 m
microporous filter. Left panel shows representative images of cells stained for EdU (cyan) and CPD (red). Right panel shows quantified EdU incorporation
levels averaged from at least 60 cells from two independent experiments. Scale bar: 5m. (C) CPD removal, as determined by immunofluorescence inU2OS,
XPF KO cells and cells expressing XPF-wt, XPF-P379S and XPF-C236R 1 min and 24 h after irradiation with 10 J/m2 UVC. CPD levels were measured
from at least 277 cells from two independent experiments, averaged and normalized to levels 1 min after UV irradiation. Statistical significant difference
(P < 0.05) compared to wt for each time point (B) or compared to 1 min after UV (C) is indicated by *.
machinery (Figure 7B and Supplementary Figures S3–S5)
as in XPF KO and nuclease-dead XPF-D715A cells, sug-
gesting that NER is not completely impaired. Similarly,
residual but slower NER activity was reported for mild XP
patient cells from XP complementation groups other than
XP-F (47–52).Our data therefore support the idea that mild
XP symptoms result from mutations in NER genes that re-
duce, but do not abolish, GG-NER activity (Figure 8).
XPF mutation C236R was identified in two XPCS pa-
tients, either as compound heterozygous with R589W or
with an allele encoding a barely expressed truncated XPF
lacking its nuclease domain (Table 1) (15). Strikingly, this
mutation affected XPF activity inNERmuchmore severely
than P379S. Similarly to nuclease-dead XPF-D715A, XPF-
C236R was persistently recruited to DNA damage (up to
24 h). This was confirmed by FRAP analyses, which, how-
ever, indicated that XPF-C236R is not statically bound to
damaged DNA. If a fraction of XPF-C236R was stati-
cally bound, its fluorescence recovery in LUD (as measured
in Figure 3D) would be expected to reach a steady-state
plateau below the level of XPF-wt, whereas instead we ob-
served continued recovery (i.e. an ascending slope), albeit
delayed, of the fluorescence signal in time. Thus, consider-
ing also the reduced nuclease activity in vitro and the low
UDS, RRS and CPD repair levels associated with this mu-
tation, as observed in our cells and previously in patient fi-
broblasts (15) (Table 1), we speculate that C236R mutant
XPF likely continuously binds and dissociates from sites of
damage because it is incapable of efficiently incising DNA.
In XPF-C236R as well as in XPF-D715A and XPF KO
cells, in which obviously no incision is made, the core NER
factors XPC, CSB, TFIIH, XPA and XPGwere also persis-
tently recruited to sites of damage. It is therefore likely that
in XPF-C236R cells the repair reaction is severely blocked
(Figure 8). The continuous presence of the core NER ma-
chinery probably reflects a futile attempt to build up a func-
tional NER complex, which is also continuously aborted
because of the absence of functional XPF. Strikingly, we ob-
served the same persistent recruitment of part of the core
NER machinery in XPCS patient fibroblasts from differ-
ent XP complementation groups as well as in DSC XPA-
deficient cells, likely because in these cells NER is strongly
blocked as well. Thus, a major difference between muta-
tions that cause only mild XP and mutations that cause ad-
ditional developmental and progressive neurodegenerative
symptoms might be that these latter mutations much more
strongly reduce, or even abolish, NER. Such strongly or
completely impaired NERmay elicit more untoward events
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Figure 7. XPC and TFIIH are continuously recruited to UV damage in
XPCS patient fibroblasts. (A) Representative immunofluorescence pictures
showing the co-localization of XPF and XPB at LUD in patient fibrob-
lasts XPCS1CD and CS1USAU, compared to wild type C5RO fibrob-
lasts. Cells were stained 1 h and 8 h after local UV irradiation (60 J/m2)
through an 8mmicroporous filter with antibodies against XPF andXPB.
(B) Representative immunofluorescence pictures showing the LUD recruit-
ment of XPD and XPC in fibroblasts derived from patients carrying muta-
tions in XPB, XPD, XPG, XPF and XPA, affected by mild XP (XP42RO,
XP32BR, XP6BE), XPCS (XPCS1CD, XPCS1BA, XPCS2, XPCS1RO)
or DSC (XP25RO) compared to wild type C5RO fibroblasts. Cells were
locally UV irradiated with 60 J/m2 UVC through an 8 m microporous
filter and stained 1 h and 8 h after irradiation with antibodies against XPD
and XPC. Scale bar: 5 m.
than simply failure to prevent mutagenesis, thus contribut-
ing to the more severe phenotype observed in XPCS and
DSC.
In the absence of NER, recovery of lesion-stalled tran-
scription is impeded. This could possibly be exacerbated
because the NER machinery is continuously binding the
same lesion in a vain attempt of repair. As a side conse-
quence, lesions may become less accessible to other repair
mechanisms, leading to permanent transcription and pos-
sibly also replication defects. This is in line with a model
previously proposed for CS in which RNA polymerase II
stuck on lesions renders lesions inaccessible to any repair
mechanism (6). Unrepaired lesions interfering with tran-
scription and replication will cause a persistent DNA dam-
age response and may induce specific cell fate decisions,
leading to senescence or cell death, which might contribute
to the more severe phenotypes observed in XPCS while re-
ducing cancer incidence as compared toXP (3,6). Also, con-
tinuous recruitment and activation of the NER machinery
may hyperactivate PARP, causing continuous PAR recy-
cling and thus higher ATP consumption, which might ul-
timately contribute to defective mitophagy often connected
to neurodegeneration observed in CS or DSC (53). Addi-
tionally, prolonged binding of DNA damage by TFIIH was
previously proposed to lead to extensive ssDNA formation
contributing to DNA break formation and genomic insta-
bility, as observed in mouse and human XPD-XPCS cells
(54,55). Based on structural analysis of a distantly related
XPD ortholog from Sulfolobus acidocaldarius (56), it was
hypothesized that XPD-XPCS mutations may reduce the
flexibility of XPD and force the protein in an abnormal
conformation that compromises TFIIH function in TC-
NER, leading to CS features (57). XP mutations in XPD,
on the other hand, may only reduce helicase activity and
DNA binding, making NER less efficient, leading to XP
and cancer. Mutational analysis in S. cerevisiae further-
more suggested that XPD-XPCS mutations still allow par-
tial DNA unwinding by TFIIH, increasing its affinity to-
wards DNA and leading to its permanent recruitment at
sites of damage, leaving TFIIHunavailable for transcription
resumption (58). Our results also resemble those observed
in mouse models with different XPG mutations. Mice car-
rying a point mutation in XPG that is predicted to affect its
endonuclease activity (D811A) show severe, but not com-
pletely impaired 6-4PP lesion removal and UV survival and
no CS features (59). In contrast, mice which XPCS mim-
icking truncating XPG mutations or lacking XPG show
stronger defects in lesion removal and UV survival and dis-
play a CS phenotype. Such severe truncating mutations in
XPG have, however, also been noted to affect other pro-
cesses besides NER, which may be causative for (part of)
the CS phenotype. For instance, severe C-terminal trun-
cation of XPG was suggested to affect its stabilization of
TFIIH, leading to dysregulation of gene expression (60),
and its non-enzymatic role in regulating homologous re-
combination and BRCA1 function (61). Similarly, it could
be that severe mutations in XPF affect other processes be-
sides NER. For instance, besides its role in DNA repair,
ERCC1-XPF has been implicated in control of gene ex-
pression by chromatin looping (together with XPG) (62)
and transcription initiation during postnatal development
(63), in which the DNA substrate on which ERCC1-XPF
acts may be similar as in NER. Thus, the inability of XPF-
C236R to incise DNA or its persistence at DNA damage
sites may impair these processes as well and lead to (some
of the) CS features. All of the different, not mutually ex-
clusive, models proposed to explain the severe XPCS phe-
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Figure 8. Model showing the difference in NER between XPF-deficient XP and XPCS cells. Left: Wild-type XPF allows efficient recruitment, endonu-
cleolytic function and subsequent release (symbolized by the dashed arrows) of ERCC1-XPF and other NER factors, resulting in efficient repair. Middle:
In XP cells with mutated XPF, such as in cells expressing the P379S mutant, XPF is less efficiently recruited to DNA damage. Repair still takes place but
at a lower rate and the NER machinery is able to dissociate normally from sites of DNA damage. As a consequence, lesions are less efficiently removed,
leading to increased mutagenesis and symptoms associated with XP. Right: In contrast, in XPCS cells with mutated XPF, such as in cells expressing the
C236R mutant, the repair reaction is severely blocked. As a consequence, the core NER machinery persistently binds to lesions, likely in a futile attempt
to build up a functional NER complex. Impaired repair and persistence of the NER machinery at DNA lesions may enhance transcription impairment
due to stalled RNA polymerase II and lead to replication defects, triggering senescence and apoptosis rather than cancer, causing the additional and severe
symptoms found in XPCS patients. The same persistent recruitment of part of the core NER machinery is observed in XPCS patient fibroblasts from
different XP complementation groups as well as in DSC XPA-deficient cells.
notype suggest severe disturbance of the normal activity
of multifunctional NER factors that eventually compro-
mises chromatin-associated processes. Our data further ex-
pand these models by showing that persistent assembly of
advanced but non-functional NER pre-incision complexes
may strongly interfere with chromatin-associated processes,
including transcription which is severely impaired after UV-
damage in XPF-C236R and XPF KO cells.
The advantage of our XPF KO system for studying func-
tionality of singleXPFmutants is clearly illustrated by anal-
ysis of the R589W mutation, which is found in both mild
and severe XP and XPCS patients as heterozygous combi-
nation with P379S, R799W, C236R or an exon 3 deletion
(Table 1) (15,19,39). XPF with this mutation localized pre-
dominantly in the cytoplasm and was unable to bind DNA
damage or rescue UV and MMC sensitivity of XPF KO
cells, clearly indicating that R589W can be considered as a
functional null mutation. Its cytoplasmic localization is in
line with the previously observed cytoplasmicXPF localiza-
tion in patient fibroblasts expressing this mutant (19). It is
thus likely that differences in symptoms observed in patients
carrying this mutation are mainly derived from differences
in the capacity of the other affected XPF allele to func-
tion in NER. Thus, patients carrying P379S besides R589W
(e.g. XP32BR; Table 1) will have residual repair and exhibit
mild XP symptoms, whereas patients carrying C236R be-
sides R589W (e.g. XPCS1CD; Table 1) will hardly have re-
pair and therefore exhibit additional CS symptoms.
Finally, we analyzed two nuclease domain mutations not
implicated in XP or XPCS but associated with defects in
ICLR and FA. S786F, identified in a breast cancer, was
shown to sensitize cells toMMC, but not toUV (40), and to
lead to defective ICL unhooking in Xenopus laevis egg ex-
tracts (20), whichwas confirmed by our damage recruitment
and UV and MMC survival analyses. R689S was found
in an FA patient together with an allele encoding a non-
expressed frameshift XPFmutant. Both the absence of typ-
ical XP features as well as analysis of patient fibroblasts sug-
gested that R689S renders XPF fully defective in ICLR but
only partially defective inNER (16) (Table 1). This was con-
firmed by mild UV but strong MMC hypersensitivity we
observed for XPF-R689S expressing cells. Previously, mu-
tation of R689 in human and its equivalent residue inXeno-
pus laevis XPF was shown to reduce XPF nuclease activity
in vitro and to diminish UV lesion removal (8,20,64). In ac-
cordance, we noticed slightly increased UV-induced immo-
bilization and delayed damage dissociation of XPF-R689S.
These results might therefore indicate that NER is mildly
retarded by this mutation because XPF is slightly less able
to performDNA incision, possibly because of defects in po-
sitioning of active site residues that carry out this incision
(64).
In summary, our analysis indicates that impaired repair
and persistence of the NER machinery at DNA lesions
characterizes cells from XP patients exhibiting additional
developmental and neurodegenerative symptoms (Figure
8). Possibly, the continuous targeting of the core NER ma-
chinery to lesions further enhances transcription impair-
ment due to stalled RNA polymerase II, resulting in addi-
tional CS-like features. It has always been difficult to grasp
how mutations within the same repair pathway and even
within the same gene lead to the complex and pleiotropic
features associated with hereditary defects in NER, espe-
cially since many mutations occur in varying compound
heterozygous combinations. Our functional analysis of sin-
gle XPF mutants exemplifies the advantage of separately
studying the impact of each individual allele. The current
advance of precise genome editing techniques will likely
ease and speed up similar approaches to scrutinize muta-
tions in other NER genes, leading to improved understand-
ing of the molecular mechanisms that underlie different
DNA repair disorders.
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